Hachisu, M <br/><br/>
[Pharmacological and clinical aspects of fluvoxamine (Depromel), the first selective serotonin reuptake inhibitor approved for clinical use employed in Japan].  [electronic resource] 

 -  Nihon yakurigaku zasshi. Folia pharmacologica Japonica  May 2000 
 - 271-9 p.  digital 
<br/><br/> Publication Type: English Abstract; Journal Article; Review 
<br/><br/><label>ISSN: </label>0015-5691 
<br/><br/><label>Standard No.: </label>10.1254/fpj.115.271  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Depression--drug therapy<br/>Disease Models, Animal<br/>Drug Approval<br/>Fluvoxamine--pharmacokinetics<br/>Humans<br/>Japan<br/>Mice<br/>Obsessive-Compulsive Disorder--drug therapy<br/>Receptors, Neurotransmitter--metabolism<br/>Selective Serotonin Reuptake Inhibitors--pharmacokinetics<br/>Time Factors